FSFarooq Syed

Farooq Syed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Farooq Syed has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multi-omics data resource of pancreatic islet and β cell responses to pro-inflammatory cytokines

    by Soumyadeep Sarkar, Javier E. Flores, Navaj Nune, Mireia Ramos-Rodriguez, Xiaoyan Yi, Arturo Roca-Rivada, Marlie M. Maestas, Austin Gluth, Farooq Syed, Young-Mo Kim, et al.

    In type 1 diabetes (T1D), autoimmune responses and inflammation cause the death of pancreatic β cells, leading to the body’s inability to produce insulin and maintain glucose homeostasis. This process is at least in part mediated by pro-inflammatory cytokines, such as interferon (IFN)α, IFNγ, interleukin (IL)-1β, and tumor necrosis factor (TNF)α, which induce β-cell dysfunction and apoptosis. A deep understanding of the β-cell signaling and regulatory networks induced by these cytokines could lead to the identification of therapeutic targets to prevent T1D development. To study cytokine-mediated islets/β-cell signaling and regulatory networks, a variety of omics experiments have been conducted, including transcriptomics, epigenomics (DNA methylation, UMI-4C, ATAC-seq and ChIP-seq), proteomics (bottom-up, top-down, post-translational modification analysis), lipidomics, and metabolomics. The combination of these datasets can be instrumental in identifying signaling components and regulatory factors involved in β-cell stress/death. Here, we aggregated 70 (multi-)omics datasets from 23 studies spanning 14 years into a centralized location, providing a comprehensive resource for investigators seeking to reuse data to holistically study the impact of pro-inflammatory cytokines on β cells.

  • Hyperosmotic niche adaptation and tissue polyamines underlie MRSA persistence in the kidney

    by Nobuhiro Kanazawa, Caroline P. Martens, Shinichi Makino, Segewkal Hawaze Heruye, Amy Zollman, Jered Myslinski, Annabelle White, Chetan Poudel, Jodi Yanagida, Farooq Syed, et al.

    Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia causes substantial morbidity, but tissue reservoirs that permit bacterial persistence remain poorly defined. Using intravenous USA300 MRSA infection in mice, multiplexed imaging, dual-species transcriptomics, host and bacterial genetics, and cell-based assays, we uncovered the renal inner medulla, the site of urine concentration, as an MRSA reservoir. In this hyperosmotic niche, MRSA evaded immune detection and co-opted tissue polyamines to sustain growth, enabling subsequent spread toward the renal cortex. Neutrophil recruitment to the inner medulla was profoundly delayed owing to osmotic inhibition of immune cell migration. Disruption of medullary osmolality with the loop diuretic furosemide accelerated neutrophil infiltration, limited bacterial spread, and improved renal outcomes. Mechanistically, polyamines promoted MRSA persistence through both extracellular and intracellular actions that depended on local osmolality and pH. In the medullary milieu, polyamines primarily associated with the bacterial surface and stabilized membranes against osmotic stress. Intracellular polyamines enhanced translation of guaB (inosine monophosphate dehydrogenase), the rate-limiting enzyme in bacterial de novo purine biosynthesis. The polyamine-catabolizing gene speG (spermidine acetyltransferase), uniquely present in epidemic USA300 MRSA strains, mitigated polyamine toxicity and conferred a selective advantage in the polyamine-rich kidney. These findings revealed the inner medulla as a physiologically immune-restricted MRSA reservoir and supported modulation of medullary osmolality and bacterial polyamine metabolism as candidate adjunctive strategies for limiting renal persistence and dissemination during MRSA bacteremia.


  • Open Access

    Beta cell microRNAs function as molecular hubs of type 1 diabetes pathogenesis and as biomarkers of diabetes risk

    by Farooq Syed, Preethi Krishnan, Garrick Chang, Jyoti Rana, Sarah R. Langlais, Sumon Hati, Kentaro Yamada, Anh K. Lam, Sayali Talware, Jacqueline Del Carmen Aquino, et al.

    Aims/hypothesis: Clinically actionable biomarkers that accurately reflect the health status of the beta cell are needed to improve risk stratification and optimise the timing of interventions in type 1 diabetes. We hypothesised that inflammatory stress elicits a reproducible microRNA (miRNA) program in human islets and islet-derived extracellular vesicles (EVs) that can be detected in plasma EVs to stratify diabetes risk, while also providing insight into molecular pathways linked to beta cell dysfunction. Methods: Human islets were exposed to IL-1β+IFN-γ, and small RNA-seq was performed on islets and islet-derived EVs. Differentially expressed miRNAs were validated in islets, using RT-PCR, in plasma-derived EVs from individuals with autoantibody positivity (AAb + ) or recent-onset type 1 diabetes and matched control individuals using ultrasensitive, label-free localised surface plasmon resonance (LSPR) biosensors, and in pancreatic sections from organ donors using in situ hybridisation and spatial feature analysis. Finally, beta cell-targeted in vivo inhibition of miR-155 was tested in the NOD mouse model. Results: Inflammatory cytokine exposure altered a restricted subset of miRNAs, identifying 20 differentially expressed miRNAs in islets and 14 in islet-derived EVs. Only two miRNAs, miR-155-5p and miR-146a-5p, were concordantly upregulated in both compartments. Machine learning prioritised an EV miRNA panel for translational validation, and custom LSPR biosensors enabled quantification of these miRNAs in plasma EVs. This plasma EV miRNA signature, consisting of miR-155-5p, miR-146a-5p, miR-30c-1-3p, miR-802 and miR-124-3p, differentiated individuals with AAb + and those with recent-onset type 1 diabetes from control individuals with good sensitivity and specificity. In pancreatic tissue, miR-155 abundance and beta cell spatial/subcellular distribution were altered in donors with AAb + and type 1 diabetes compared with non-diabetic control individuals. Functionally, beta cell-targeted inhibition of miR-155 improved glucose tolerance and reduced insulitis in prediabetic NOD mice. Conclusions/interpretation: Using an organ-based model system of inflammatory stress, we validated a signature of EV-associated miRNAs capable of stratifying type 1 diabetes risk. Furthermore, we provided new mechanistic and imaging insights into miRNA expression patterns in pancreatic sections from human organ donors with type 1 diabetes or AAb + , and we used a preclinical model of type 1 diabetes to demonstrate the potential therapeutic efficacy of targeting these miRNAs. Data availability: The data from small RNA sequencig of human islets and islet-derived EVs have been deposited in the GEO database (accession no. GSE160391).


  • Open Access

    Soluble LAG-3 Identifies a Dynamic Early T Cell Activation Window in self-reactivity, Type 1 Diabetes, and Broader Immune Responses

    by Saptarshi Roy, Megan Lynn Proffer, Farooq Syed, Megan E. Smithmyer, Avinil Das Sharma, Abigail Twoy, Emily Soo-Hoo, Jyoti Rana, Jason M. Spaerth, Everett Meyer, et al.

    Aims/hypothesis: Type 1 diabetes is a complex autoimmune disorder in which autoreactive CD4⁺ and CD8⁺ T cells destroy pancreatic beta-cells, resulting in insulin deficiency and hyperglycemia. Although genetic susceptibility, particularly certain HLA alleles, contributes to disease risk, not all genetically predisposed individuals develop Type 1 diabetes. Screening first degree relatives (FDRs) for islet autoantibodies (GAD65, IAA, IA-2, ZnT8) helps detect autoimmune activity. However, these serum markers arise only after T-helper cell activation, limiting early intervention opportunities. Since protein antigen recognition by B cells requires T-helper cell assistance through linked recognition, T cell activation precedes B cell activation and autoantibody production. Activation of these T cells leads to shedding of the immune-regulatory (activation) surface protein LAG-3 (Lymphocyte Activation Gene-3 or CD223), generating its soluble form, sLAG-3, that is detectable in circulation. We hypothesized that sLAG-3 may serve as an early biomarker of autoimmune activity preceding islet autoantibody development in type 1 diabetes. Methods: Plasma sLAG-3 levels were measured longitudinally in female diabetes-prone NOD mice and analyzed in relation to islet antigen-specific CD4⁺ T cell expansion and diabetes onset. To mechanistically link autoreactive T cell activation to sLAG-3 release. Naive autoreactive C6.6.9 TCR-transgenic (TCR-Tg) CD4⁺ T cells were adoptively transferred into NOD.SCID mice and longitudinal assessment for plasma sLAG-3, beta-cell antigen specific CD4⁺ T cell tetramer profiles, and circulating insulin ( Ins2 ) mRNA to determine ongoing beta-cell stress. In parallel, sLAG-3 levels were analyzed from different human cohorts, including FDRs of individuals with type 1 diabetes, using cross-sectional and longitudinal approaches. Results: In murine models, elevated sLAG-3 correlated with expansion of islet-specific CD4⁺ T cells that preceded hyperglycemia and diabetes onset. In the adoptive transfer model, early increases in sLAG-3 and circulating Ins2 mRNA marked immune activation and emerging beta-cell stress prior to overt diabetes. In our human cohorts, sLAG-3 was detectable in autoantibody-negative and single-autoantibody-positive FDRs, with higher levels observed in progressors compared to non-progressors, and associated with high-risk HLA genotypes. Conclusions/interpretation: These findings identify sLAG-3 as a candidate biomarker of early T cell activation in type 1 diabetes that may precede islet autoantibody development. Integration of sLAG-3 with antigen-specific T cell and beta-cell stress markers could improve early risk stratification and inform preventive strategies before substantial loss of beta-cell. Prospective longitudinal studies aligned to seroconversion are required to validate sLAG-3 as a surrogate marker of early disease activity. Research in context: What is already known about this subject?: Before the clinical onset of hyperglycemia, type 1 diabetes is characterized by a prolonged preclinical phase in which autoreactive B and T cells mediate progressive beta-cell destruction. Current risk stratification strategies rely mainly on genetic susceptibility (genomic DNA) and the detection of islet autoantibodies in plasma/serum. Islet autoantibodies arise only after CD4⁺ T cell activation and therefore do not capture the earliest stages of immune dysregulation. Consequently, biomarkers that directly reflect early pathogenic T cell activity prior to, or independent of, seroconversion remain limited and insufficiently validated. What is the key question?: Can plasma sLAG-3 levels, beta-cell antigen-specific CD4⁺ T cell tetramer expression, and circulating Ins2 mRNA serve as very early biomarkers of autoimmune activity in type 1 diabetes and serve to better inform risk stratification, thereby informing preventive intervention strategies for the clinician? What are the new findings?: sLAG-3 increases transiently during early antigen-specific CD4⁺ T cell activation stage, precedes hyperglycemia in mouse models, and is elevated in autoantibody-negative and single-autoantibody-positive first-degree relatives who later progress to type 1 diabetes. sLAG-3 was associated with beta-cell antigen-specific CD4⁺ T cell expansion, assessment of stress induced beta cell Ins2 mRNA release and high-risk HLA genotypes, indicating early autoimmune activation rather than established disease. How might this impact clinical practice in the foreseeable future?: These findings support sLAG-3 as a candidate early biomarker of T cell activation, before or at the earliest stages of islet autoantibody development in some at-risk individuals. Integration of plasma sLAG-3 with beta-cell antigen specific CD4⁺ T cell profiling and insulin mRNA measurements could complement current autoantibody-based screening, improve risk stratification, and enable earlier preventive interventions to preserve beta-cell function in patients at-risk for type 1 diabetes.


  • Open Access

    Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice

    by Farooq Syed, Olivia Ballew, Chih-Chun Lee, Jyoti Rana, Preethi Krishnan, Angela Castela, Staci A. Weaver, Namratha Shivani Chalasani, Sofia F. Thomaidou, Stephane Demine, et al.


  • Open Access

    miR-146a-5p mediates inflammation-induced β cell mitochondrial dysfunction and apoptosis

    by Preethi Krishnan, Renato Chaves Souto Branco, Staci A. Weaver, Garrick Chang, Chih-Chun Lee, Farooq Syed, Carmella Evans-Molina


  • Open Access

    Sodium butyrate prevents cytokine‐induced β‐cell dysfunction through restoration of stromal interaction molecule 1 expression and activation of store‐operated calcium entry

    by Chih‐Chun Lee, Tatsuyoshi Kono, Farooq Syed, Staci A. Weaver, Paul Sohn, Wenting Wu, Garrick Chang, Jing Liu, Marjan Slak Rupnik, Carmella Evans‐Molina

    Sodium butyrate (NaB) improves β‐cell function in preclinical models of diabetes; however, the mechanisms underlying these beneficial effects have not been fully elucidated. In this study, we investigated the impact of NaB on β‐cell function and calcium (Ca 2+ ) signaling using ex vivo and in vitro models of diabetes. Our results show that NaB significantly improved glucose‐stimulated insulin secretion in islets from human organ donors with type 2 diabetes and in cytokine‐treated INS‐1 β cells. Consistently, NaB improved glucose‐stimulated Ca 2+ oscillations in mouse islets treated with proinflammatory cytokines. Because the oscillatory phenotype of Ca 2+ in the β cell is governed by changes in endoplasmic reticulum (ER) Ca 2+ levels, we explored the relationship between NaB and store‐operated calcium entry (SOCE), a rescue mechanism that acts to refill ER Ca 2+ levels through STIM1‐mediated gating of plasmalemmal Orai channels. We found that NaB treatment preserved basal ER Ca 2+ levels and restored SOCE in IL‐1β‐treated INS‐1 cells. Furthermore, we linked these changes with the restoration of STIM1 levels in cytokine‐treated INS‐1 cells and mouse islets, and we found that NaB treatment was sufficient to prevent β‐cell death in response to IL‐1β treatment. Mechanistic experiments revealed that NaB mediated these beneficial effects in the β‐cell through histone deacetylase (HDAC) inhibition, iNOS suppression, and modulation of AKT‐GSK‐3 signaling. Taken together, these data support a model whereby NaB treatment promotes β‐cell function and Ca 2+ homeostasis under proinflammatory conditions through pleiotropic effects that are linked with maintenance of SOCE. These results also suggest a relationship between β‐cell SOCE and gut microbiome‐derived butyrate that may be relevant in the treatment and prevention of diabetes.


  • Open Access

    miR-146a-5p mediates inflammation-induced β cell mitochondrial dysfunction and apoptosis

    by Preethi Krishnan, Renato Chaves Souto Branco, Staci A. Weaver, Garrick Chang, Chih-Chun Lee, Farooq Syed, Carmella Evans-Molina

    We previously showed that miR-146a-5p is upregulated in pancreatic islets treated with pro-inflammatory cytokines. Others have reported that miR-146a-5p overexpression is associated with β cell apoptosis and impaired insulin secretion. However, the molecular mechanisms mediating these effects remain elusive. To investigate the role of miR-146a-5p in β cell function, we developed stable MIN6 cell lines to either overexpress or inhibit the expression of miR-146a-5p. Monoclonal cell populations were treated with pro-inflammatory cytokines (IL-1β, IFN γ , and TNFα) to model type 1 diabetes (T1D) in vitro . We found that overexpression of miR-146a-5p increased cell death under conditions of inflammatory stress and led to mitochondrial membrane depolarization, whereas inhibition of miR-146a-5p reversed these effects. Additionally, inhibition of miR-146a-5p increased insulin secretion, mitochondrial DNA copy number, respiration rate, and ATP production Further, RNA sequencing data showed enrichment of pathways related to insulin secretion, apoptosis, and mitochondrial function when the expression levels of miR-146a-5p were altered. Finally, a temporal increase in miR-146a-5p expression levels and a decrease in mitochondria function markers was observed in islets derived from NOD mice. Collectively, these data suggest that miR-146a-5p may promote β cell dysfunction and death during inflammatory stress by suppressing mitochondrial function.


  • Open Access

    A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease

    by Victor Hugo Canela, William S. Bowen, Ricardo Melo Ferreira, Farooq Syed, James E. Lingeman, Angela R. Sabo, Daria Barwinska, Seth Winfree, Blue B. Lake, Ying-Hua Cheng, et al.

    Kidney stone disease causes significant morbidity and increases health care utilization. In this work, we decipher the cellular and molecular niche of the human renal papilla in patients with calcium oxalate (CaOx) stone disease and healthy subjects. In addition to identifying cell types important in papillary physiology, we characterize collecting duct cell subtypes and an undifferentiated epithelial cell type that was more prevalent in stone patients. Despite the focal nature of mineral deposition in nephrolithiasis, we uncover a global injury signature characterized by immune activation, oxidative stress and extracellular matrix remodeling. We also identify the association of MMP7 and MMP9 expression with stone disease and mineral deposition, respectively. MMP7 and MMP9 are significantly increased in the urine of patients with CaOx stone disease, and their levels correlate with disease activity. Our results define the spatial molecular landscape and specific pathways contributing to stone-mediated injury in the human papilla and identify associated urinary biomarkers.


  • Open Access

    β Cell microRNAs Function as Molecular Hubs of Type 1 Diabetes Pathogenesis and as Biomarkers of Diabetes Risk

    by Farooq Syed, Preethi Krishnan, Garrick Chang, Sarah R. Langlais, Sumon Hati, Kentaro Yamada, Anh K. Lam, Sayali Talware, Xiaowen Liu, Rajesh Sardar, et al.

    MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in modulating gene expression and are enriched in cell-derived extracellular vesicles (EVs). We investigated whether miRNAs from human islets and islet-derived EVs could provide insight into β cell stress pathways activated during type 1 diabetes (T1D) evolution, therefore serving as potential disease biomarkers. We treated human islets from 10 cadaveric donors with IL-1β and IFN-γ to model T1D ex vivo . MicroRNAs were isolated from islets and islet-derived EVs, and small RNA sequencing was performed. We found 20 and 14 differentially expressed (DE) miRNAs in cytokine-versus control-treated islets and EVs, respectively. Interestingly, the miRNAs found in EVs were mostly different from those found in islets. Only two miRNAs, miR-155-5p and miR-146a-5p, were upregulated in both islets and EVs, suggesting selective sorting of miRNAs into EVs. We used machine learning algorithms to rank DE EV-associated miRNAs, and developed custom label-free Localized Surface Plasmon Resonance-based biosensors to measure top ranked EVs in human plasma. Results from this analysis revealed that miR-155, miR-146, miR-30c, and miR-802 were upregulated and miR-124-3p was downregulated in plasma-derived EVs from children with recent-onset T1D. In addition, miR-146 and miR-30c were upregulated in plasma-derived EVs of autoantibody positive (AAb+) children compared to matched non-diabetic controls, while miR-124 was downregulated in both T1D and AAb+ groups. Furthermore, single-molecule fluorescence in situ hybridization confirmed increased expression of the most highly upregulated islet miRNA, miR-155, in pancreatic sections from organ donors with AAb+ and T1D. One Sentence Summary: miRNA expression patterns in human pancreatic islets and EVs change under inflammatory conditions and can be leveraged to inform biomarkers strategies for T1D.